BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 16101557)

  • 1. Neurodegenerative pathways in Parkinson's disease: therapeutic strategies.
    Cardoso SM; Moreira PI; Agostinho P; Pereira C; Oliveira CR
    Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):405-19. PubMed ID: 16101557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
    McNaught KS; Jnobaptiste R; Jackson T; Jengelley TA
    Synapse; 2010 Mar; 64(3):241-50. PubMed ID: 19924695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of pathogenesis of Parkinson's disease.
    Shadrina MI; Slominsky PA; Limborska SA
    Int Rev Cell Mol Biol; 2010; 281():229-66. PubMed ID: 20460187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
    Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
    J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease.
    Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):271-82. PubMed ID: 15580550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What lysosomes actually tell us about Parkinson's disease?
    Bourdenx M; Dehay B
    Ageing Res Rev; 2016 Dec; 32():140-149. PubMed ID: 26947123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
    Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
    J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein, lipids and Parkinson's disease.
    Ruipérez V; Darios F; Davletov B
    Prog Lipid Res; 2010 Oct; 49(4):420-8. PubMed ID: 20580911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
    Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
    Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current perspective of mitochondrial biology in Parkinson's disease.
    Ammal Kaidery N; Thomas B
    Neurochem Int; 2018 Jul; 117():91-113. PubMed ID: 29550604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathological mechanisms of Parkinson's disease].
    Matsui H; Takahashi R
    Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.
    Sulzer D
    Trends Neurosci; 2007 May; 30(5):244-50. PubMed ID: 17418429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.